Clovis Oncology (NASDAQ:CLVSQ) Versus Oncotelic Therapeutics (OTCMKTS:OTLC) Head-To-Head Contrast
Clovis Oncology (NASDAQ:CLVSQ) Versus Oncotelic Therapeutics (OTCMKTS:OTLC) Head-To-Head Contrast
Clovis Oncology (NASDAQ:CLVSQ – Get Rating) and Oncotelic Therapeutics (OTCMKTS:OTLC – Get Rating) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings and valuation.
Clovis Oncology（納斯達克股票代碼：CLVSQ — 獲取評級）和Oncotelic Therapeutics（OTCMKTS: OTLC — 獲取評級）都是小型醫療公司，但哪家業務更勝一籌？我們將根據兩家公司的股息強度、分析師建議、機構所有權、風險、盈利能力、收益和估值對比這兩家公司。
Profitability
盈利能力
This table compares Clovis Oncology and Oncotelic Therapeutics' net margins, return on equity and return on assets.
該表比較了Clovis Oncology和Oncotelic Therapeutics的淨利潤率、股本回報率和資產回報率。
| Net Margins | Return on Equity | Return on Assets | |
| Clovis Oncology | -189.37% | N/A | -57.78% |
| Oncotelic Therapeutics | N/A | -53.27% | -26.26% |
| 淨利潤 | 股本回報率 | 資產回報率 | |
| 克洛維斯腫瘤學 | -189.37% | 不適用 | -57.78% |
| Oncotelic 療法 | 不適用 | -53.27% | -26.26% |
Analyst Recommendations
分析師建議
This is a breakdown of recent ratings and price targets for Clovis Oncology and Oncotelic Therapeutics, as reported by MarketBeat.
據MarketBeat報道，這是Clovis Oncology和Oncotelic Therapeutics最近的評級和目標價格的明細。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Clovis Oncology | 0 | 0 | 0 | 0 | N/A |
| Oncotelic Therapeutics | 0 | 0 | 0 | 0 | N/A |
| 賣出評級 | 持有評級 | 買入評級 | 強勁的買入評級 | 評分分數 | |
| 克洛維斯腫瘤學 | 0 | 0 | 0 | 0 | 不適用 |
| Oncotelic 療法 | 0 | 0 | 0 | 0 | 不適用 |
Earnings & Valuation
收益與估值
This table compares Clovis Oncology and Oncotelic Therapeutics' revenue, earnings per share and valuation.
該表比較了Clovis Oncology和Oncotelic Therapeutics的收入、每股收益和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Clovis Oncology | $148.76 million | 0.02 | -$264.52 million | ($1.83) | -0.01 |
| Oncotelic Therapeutics | $1.74 million | 9.01 | -$9.39 million | $0.03 | 1.33 |
| 總收入 | 價格/銷售比率 | 淨收入 | 每股收益 | 市盈率 | |
| 克洛維斯腫瘤學 | 1.4876 億美元 | 0.02 | -2.6452 億美元 | (1.83 美元) | -0.01 |
| Oncotelic 療法 | 174 萬美元 | 9.01 | -939 萬美元 | 0.03 美元 | 1.33 |
Oncotelic Therapeutics has lower revenue, but higher earnings than Clovis Oncology. Clovis Oncology is trading at a lower price-to-earnings ratio than Oncotelic Therapeutics, indicating that it is currently the more affordable of the two stocks.
Oncotelic Therapeutics的收入較低，但收益高於克洛維斯·腫瘤學。Clovis Oncology的市盈率低於Oncotelic Therapeutics，這表明它目前是這兩隻股票中更實惠的一隻。
Insider and Institutional Ownership
內部所有權和機構所有權
24.5% of Clovis Oncology shares are held by institutional investors. 4.4% of Clovis Oncology shares are held by company insiders. Comparatively, 39.2% of Oncotelic Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
24.5％的Clovis Oncology股份由機構投資者持有。4.4％的Clovis Oncology股份由公司內部人士持有。相比之下，Oncotelic Therapeutics39.2％的股份由公司內部人士持有。強大的機構所有權表明，大型基金經理、對沖基金和捐贈基金認爲股票有望實現長期增長。
Volatility & Risk
波動性與風險
Clovis Oncology has a beta of 0.9, meaning that its share price is 10% less volatile than the S&P 500. Comparatively, Oncotelic Therapeutics has a beta of 0.66, meaning that its share price is 34% less volatile than the S&P 500.
Clovis Oncology的beta值爲0.9，這意味着其股價的波動性比標準普爾500指數低10％。相比之下，Oncotelic Therapeutics的beta值爲0.66，這意味着其股價的波動性比標準普爾500指數低34％。
Summary
摘要
Oncotelic Therapeutics beats Clovis Oncology on 7 of the 11 factors compared between the two stocks.
比較兩隻股票的11個因素中，Oncotelic Therapeutics在7個因素上擊敗了克洛維斯腫瘤學。
About Clovis Oncology
關於克洛維斯腫瘤學
(Get Rating)
（獲取評級）
Clovis Oncology, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of innovative anti-cancer agents in the United States, Europe, and additional international markets. Its U.S. marketed product, Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP), is approved for use in the maintenance treatment and treatment of eligible adult patients with recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer, and also for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC), which have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. In Europe, Rubraca is approved for use in recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy, and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO.
Clovis Oncology, Inc. 是一家生物製藥公司，在美國、歐洲和其他國際市場從事創新抗癌藥物的收購、開發和商業化。其在美國上市的產品Rubraca（rucaparib）是一種聚ADP-核糖聚合酶（PARP）的口服小分子抑制劑，獲准用於複發性上皮性卵巢癌、輸卵管癌和原發性腹膜癌的合格成人患者的維持治療和治療，也用於治療有害的BRCA突變（種系和/或體細胞相關性）的成年患者轉移性去勢抵抗性前列腺癌（mcRPC），已通過雄激素受體定向療法和紫杉烷化療進行治療。在歐洲，Rubraca被批准用於複發性上皮性卵巢癌、輸卵管癌或原發性腹膜癌。該公司由 Andrew R. Allen、Gillian C. Ivers-Read、Patrick J. Mahaffy 和 Erle T. Mast 於 2009 年 4 月 20 日創立，總部位於科羅拉多州博爾德。
About Oncotelic Therapeutics
關於 Oncotelic Therapeut
(Get Rating)
（獲取評級）
Oncotelic Therapeutics, Inc. is a biopharmaceutical company. It engages in developing anti-vascular therapeutics for patients with cancer and sight-threatening eye diseases. The company is currently developing OT-101 for various cancers and COVID-19, Artemisinin for COVID-19 and AI technologies for clinical development and manufacturing. Oncotelic Therapeutics was founded in 1988 and is headquartered in Agoura Hills, CA.
Oncotelic Therapeutics, Inc. 是一家生物製藥公司。它致力於爲癌症和危及視力的眼病患者開發抗血管療法。該公司目前正在開發用於各種癌症的 OT-101 和用於 COVID-19 的 COVID-19、青蒿素以及用於臨牀開發和製造的人工智能技術。Oncotelic Therapeutics成立於1988年，總部位於加利福尼亞州阿古拉山。
Receive News & Ratings for Clovis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
接收《克洛維斯腫瘤學日報》的新聞和評級 -在下面輸入您的電子郵件地址，即可通過Marketbeat.com的免費每日電子郵件時事通訊接收Clovis Oncology及相關公司的最新新聞和分析師評級的簡明每日摘要。
譯文內容由第三人軟體翻譯。